Stocks - US OTC - Banking and Finance Message Boards

Board Name	Total Posts	Latest Post
Fannie Mae No Politics	824,164	03/29/2025 11:47:26 AM
All Things Mobile Analytic Inc	110,405	03/29/2025 11:42:40 AM
Lehman Brothers Financial SA	112,764	03/29/2025 10:54:01 AM
Global Developments Inc	24,350	03/29/2025 09:32:56 AM
Freddie Mac No Politics	47,306	03/29/2025 06:13:40 AM
FDCTech Inc	3,209	03/28/2025 04:04:47 PM
CLST Holdings Inc	32,926	03/28/2025 01:08:27 PM
Innovative Payment Solutions Inc	5,497	03/27/2025 09:57:38 PM
Third Bench Inc	84,959	03/27/2025 09:18:55 PM
Hamilton Bancorp Inc	17	03/25/2025 01:35:59 PM
APT Systems Inc	13,938	03/22/2025 01:37:03 PM
Real American Capital Corp	10,415	03/17/2025 01:02:50 PM
Global Arena Holding Inc	32,548	03/17/2025 11:46:36 AM
Affiliated Resources Corp	578	03/15/2025 06:36:50 PM
UpStart Holdings Inc	205	03/14/2025 08:21:25 AM
Capital Financial Global Inc	49,079	03/11/2025 10:46:22 AM
LM Funding America Inc	2,114	03/07/2025 02:45:05 PM
Town Center Bank	19	03/07/2025 01:30:37 AM
Loans4Less com	329	03/06/2025 06:29:44 AM
Sunset Capital Assets Inc	5,972	02/27/2025 02:04:22 PM

Board	Rate*
Global Developments Inc (GDVM)	400%
Niocorp Developments Ltd (NB)	253%
Mr Cooper Group Inc (COOP)	243%
Biotech Values	238%
DD Support Board and Research Team	230%

Play Episode

6min

Proactive - Interviews for investors

Race Oncology’s RC220 trial gets green light

Race Oncology Ltd chair Peter Smith talked with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with its clinical trial for RC220, a new formulation of bisantrene. Smith explained that the trial aims to establish the safety of RC220 both as a standalone treatment and in combination with doxorubicin, a commonly used chemotherapy drug. "What we’ll be seeking to achieve is establishing the maximum tolerated dose for the combination of the two drugs together," he said. The study will also investigate whether RC220 can reduce doxorubicin’s known toxicity to the cardiovascular system. Smith highlighted that doxorubicin can cause permanent heart damage, potentially reducing patient lifespan by the equivalent of a decade. The company aims to demonstrate that RC220 can enhance anti-cancer effects while mitigating heart-related side effects. The trial will be conducted in multiple phases, beginning in Australia, with expansion planned into Korea and Hong Kong later in the year. Smith noted that the Cancer Care Foundation is playing a role in patient support and accessibility. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future updates. #RaceOncology #CancerResearch #ClinicalTrial #Biotech #Oncology #RC220 #Doxorubicin #CardioProtection #Pharma #MedicalResearch #CancerTreatment

Proactive - Interviews for investors

KRM22 CEO on risk management, compliance & growth plans

KRM22 CEO Dan Carter talked with Proactive's Stephen Gunnion about the company’s mission to provide integrated risk management solutions for capital markets. Founded in 2018, KRM22 has developed a suite of tools that help firms manage trading and corporate risk more efficiently. Carter explained that capital markets have traditionally relied on siloed risk tools. KRM22 has worked to integrate these tools into a holistic platform. The company’s solutions cover intraday risk management, pre-trade limit controls, market surveillance, and enterprise risk tracking. “We've created a digitised risk register that helps bring those data points together and validate assessments,” he said. The discussion also covered the impact of regulatory changes post-Covid. Carter highlighted that regulators are now scrutinising risk management practices more closely. He emphasised that KRM22’s tools help firms demonstrate compliance, reducing the risk of regulatory penalties. On growth, Carter noted that KRM22’s annual recurring revenue (ARR) is now around £7 million, with a recent customer contract further strengthening the company’s financial position. Looking ahead, KRM22 is exploring AI-driven enhancements, particularly in market surveillance, to detect potential compliance issues before they become violations. For more insights, watch the full interview. Don't forget to like the video, subscribe to Proactive's channel, and turn on notifications for updates! #KRM22 #RiskManagement #CapitalMarkets #TradingRisk #RegTech #MarketSurveillance #FinancialCompliance #AIinFinance #CorporateRisk #Investing

Proactive - Interviews for investors

St George Mining’s dual track growth plan

St George Mining Ltd executive chairman John Prineas talked with Kerry Stevenson at Proactive about the company's recent acquisition of the Araxá niobium and rare earths project in Brazil. The deal, completed in February, provides St George with an advanced-stage project with high-grade niobium and rare earth elements. Prineas highlighted niobium’s strategic importance, noting that it is primarily used to strengthen steel, with additional applications in medical technology, batteries, and defence. He emphasised the commodity's stable pricing due to limited global supply. The company secured A$20 million in funding to advance the project and is preparing a JORC-compliant mineral resource estimate, expected in the coming weeks. The existing data, based on historical drilling, indicates a 20-year mine life and a US$956 million NPV under a previous non-JORC study. St George aims to optimise the project for niobium, conduct further drilling, and expand the resource. Prineas also addressed Brazil's mining jurisdiction, highlighting strong government support and agreements to expedite approvals. The company is pursuing a dual-track strategy, progressing toward development while ramping up exploration drilling to expand the resource base. Stay tuned for more updates! Visit Proactive's YouTube channel for more interviews, and don’t forget to like, subscribe, and turn on notifications. #StGeorgeMining #ASXSGQ #Niobium #RareEarths #MiningStocks #JORC #BrazilMining #CriticalMetals #ResourceInvestment #BatteryMetals

Proactive - Interviews for investors

Imugene’s Azercell shows strong response in blood cancer

Imugene Ltd CEO Leslie Chong talked with Kerry Stevenson at Proactive about the FDA's fast-track designation for its immunotherapy candidate, Azercell. The therapy, an allogeneic off-the-shelf CAR-T treatment, has shown promising results in patients with diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of blood cancer. Chong highlighted that four out of seven patients treated with Azercell achieved complete response, meaning their cancer was no longer detectable. The longest response duration has now exceeded 11 months. “The FDA has recognised the importance of a product like this and has given us fast-track designation,” Chong stated. The FDA's fast-track status allows Imugene to expedite regulatory discussions and move towards potential commercialization more efficiently. The company sees this as a critical milestone, with Chong emphasising that the priority now is gathering sufficient data to advance towards registration studies. With an estimated 80,000 new DLBCL cases diagnosed annually in the US, Azercell could address a significant unmet need, especially for patients who have exhausted other treatment options. For more updates on Imugene and other biotech innovations, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future content. #Imugene #Biotech #CancerResearch #FDA #CAR_T #Oncology #BloodCancer #DLBCL #MedicalBreakthrough #FastTrack #Immunotherapy

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Breakout Boards

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Breakout Boards

Go Ad-Free